https://via.tt.se/pressmeddelande/3995569/european-commission-approves-tevimbra-r-in-combination-with-chemotherapy-as-a-first-line-treatment-for-nasopharyngeal-carcinoma?publisherId=259167&lang=en
European Commission Approves TEVIMBRA ® in Combination with Chemotherapy as a First-Line Treatment...
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA®...
first line treatmenteuropean commissionapprovestevimbracombination
https://www.kusuri.net/approved/tevimbra/
TEVIMBRA (ティシレリツマブ：TISLELIZUMAB) | クスリネット
承認日：2024年3月13日社名：BEIGENE医薬品名：TEVIMBRA主成分名：ティシレリツマブ：TISLELIZUMAB含有量：100MG/10ML剤形：INJECTION;SOLUTION適応：切除不能または転移性食道扁平（へん
tevimbra